Demand for chiari malformation treatment will increase through 2036, with Type 1 cases at 54.6% of the clinical classification in 2026. The market was valued at USD 2.61 billion in 2025 and is expected to be worth USD 5.07 billion by 2036, creating an incremental opportunity of USD 2.34 billion.